You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

I am a:
${ profile.name.substring(0, profile.name.length - 1) }
Request Info

Xpert® vanA/vanB

Fast & Accurate Detection of Vancomycin-Resistant Enterococci (VRE) in Around 45 Minutes

Product Resources MyCepheid Store
Xpert<sup>®</sup>&nbsp;<em>vanA/vanB</em>

The Need

VRE: A growing concern

The rapid and continuous increase in the percentage of VRE carriage in the EU/EEA is a cause for concern.2

  • Infections and deaths attributable to VRE almost doubled between 2007-20152
  • The population-weighted mean percentage for VRE increased from 10.5% in 2015 to 17.3% in 20182
  • High resistance levels have been reported from all regions in Europe2
  • VRE has a significant impact on patient length of stay, and in turn, hospitalization costs3

The Solution

VRE has become a substantive and growing burden in hospitalised patients, prompting the need for earlier and accurate detection.

Xpert vanA/vanB enables:

  • Fast identification of VRE in around 45 minutes
  • Laboratory efficiencies with on-demand workflows requiring minimal hands-on time, 24/7
  • Timely infection control measures to reduce transmission and outbreaks, and enable appropriate use of isolation facilities

The Impact

Fast and accurate PCR testing with Xpert®vanA/vanB greatly improves time to result, allowing healthcare professionals to quickly and appropriately manage patients, reducing transmission and enabling more efficient bed management.4

Optimize Workflow and Patient Management

  • Deliver actionable results to clinicians and infection control teams in around 45 minutes
  • On-demand STAT testing provides results 24/7
  • Ease of use and minimal hands-on-time enables more efficient use of staff time

(1) Birgand G, et al. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrob Rest Infec Control. 2013 Nov;2(30).
(2) ECDC Surveillance Report. Surveillance of antimicrobial resistance in Europe 2018. Accessed Jun 2021. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018
(3) Hemapanpairoa J, et al. Does vancomycin resistance increase mortality? Clinical outcomes and predictive factors for mortality in patients with Enterococcus faecium infections. Antibiotics. 2021 Jan;10(2):105.
(4) Saliba R, et al. Can real-time polymerase chain reaction allow a faster recovery of hospital activity in cases of an incidental discovery of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci carriers? J Hosp Infect. 2019 Oct;103(2).

Ordering Info

Xpert® vanA/vanB

Number of Tests: 10

Catalog #: GXVANA/B-CE-10

Xpert® vanA/vanB

Number of Swabs: 50

Catalog #: 900-0370
Back to Top